Tyra BiosciencesTYRA
Market Cap: $1.28B
About: Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Employees: 38
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
3% more funds holding
Funds holding: 77 [Q1] → 79 (+2) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
0.17% less ownership
Funds ownership: 89.28% [Q1] → 89.1% (-0.17%) [Q2]
3% less capital invested
Capital invested by funds: $769M [Q1] → $749M (-$20.4M) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Oppenheimer Matthew Biegler 40% 1-year accuracy 8 / 20 met price target | 36%upside $33 | Outperform Maintained | 19 Sept 2024 |
Piper Sandler Christopher Raymond 35% 1-year accuracy 7 / 20 met price target | 36%upside $33 | Overweight Initiated | 15 Aug 2024 |
Wedbush Robert Driscoll 39% 1-year accuracy 9 / 23 met price target | 15%upside $28 | Outperform Reiterated | 8 Aug 2024 |
Oppenheimer Matthew Biegler 40% 1-year accuracy 8 / 20 met price target | 3%upside $25 | Outperform Maintained | 8 Aug 2024 |
Oppenheimer Matthew Biegler 40% 1-year accuracy 8 / 20 met price target | 15%upside $28 | Outperform Reiterated | 3 Jul 2024 |
Financial journalist opinion
Based on 31 articles about TYRA published over the past 30 days